AstraZeneca

Oncology

12 Questions with Jorge Reis-Filho

As Vice President of Cancer Biomarker Development at AstraZeneca, Jorge Reis-Filho seeks to develop and validate the next generation of mechanistically informed and clinically deployable bi

News

Surprise Enhertu rejection follows NICE process change

NICE has rejected the use of AstraZeneca and Daiichi Sankyo’s Enhertu as an NHS treatment for advanced HER2-low breast cancer, a decision that the companies have described

News

EMA starts twin reviews of AZ, Daiichi’s Dato-DXd

The clock has started ticking in the EU on two marketing applications for AstraZeneca and Daiichi Sankyo’s TROP2-targeting antibody-drug conjugate datopotamab deruxtecan i

News

Judge knocks back AstraZeneca’s IRA challenge

AstraZeneca’s legal challenge to Medicare’s drug pricing negotiation powers has stumbled at the first hurdle in a federal court.

Market Access

Scaling innovation across hospitals and nations

Creating healthcare interventions and technological solutions that work is hard enough. But when the goal is sustainable system-wide improvement, it’s the easy part.

News

CHMP backs AZ’s danicopan for anaemia in patients with PNH

AstraZeneca has moved a step closer to EU approval of oral Factor D inhibitor danicopan in the EU, after the EMA’s human medicines committee, the CHMP, backed the drug as

12 Questions with Jorge Reis-Filho

Surprise Enhertu rejection follows NICE process change

EMA starts twin reviews of AZ, Daiichi’s Dato-DXd

Judge knocks back AstraZeneca’s IRA challenge

Scaling innovation across hospitals and nations

CHMP backs AZ’s danicopan for anaemia in patients with PNH

Ambrosia's sweet $100m round, and other biofinancings

Using AI-driven synthetic personas to take your insights fur...

AstraZeneca

Editor's Picks